Literature DB >> 3150477

Positron emission tomography in three cases of Lennox-Gastaut syndrome.

T Miyauchi1, Y Nomura, S Ohno, H Kishimoto, M Matsushita.   

Abstract

The true responsible lesion of Lennox-Gastaut syndrome was not adequately elucidated. Three cases of this syndrome were investigated by using Positron Emission Tomography (PET). PET revealed the differences in the left and right sides, especially the hypometabolism from the frontal to temporal regions. With this finding we supposed that the L-G syndrome implies one type of partial epilepsy caused by damage in parts of the temporal or frontal lobe.

Entities:  

Mesh:

Year:  1988        PMID: 3150477     DOI: 10.1111/j.1440-1819.1988.tb01168.x

Source DB:  PubMed          Journal:  Jpn J Psychiatry Neurol        ISSN: 0912-2036


  5 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

2.  Understanding Lennox-Gastaut syndrome: insights from focal epilepsy patients with Lennox-Gastaut features.

Authors:  Sophie Dupont; Raluca Banica-Wolters; Isabelle An-Gourfinkel; Virginie Lambrecq; Vincent Navarro; Claude Adam; Vi-Huong Nguyen-Michel
Journal:  J Neurol       Date:  2017-06-05       Impact factor: 4.849

3.  Focal abnormalities detected by 18FDG PET in epileptic encephalopathies.

Authors:  C D Ferrie; M Maisey; T Cox; C Polkey; S F Barrington; C P Panayiotopoulos; R O Robinson
Journal:  Arch Dis Child       Date:  1996-08       Impact factor: 3.791

4.  Cortical and subcortical glucose metabolism in childhood epileptic encephalopathies.

Authors:  C D Ferrie; P K Marsden; M N Maisey; R O Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

Review 5.  Conceptualizing lennox-gastaut syndrome as a secondary network epilepsy.

Authors:  John S Archer; Aaron E L Warren; Graeme D Jackson; David F Abbott
Journal:  Front Neurol       Date:  2014-10-30       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.